Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma : updated data with mivavotinib (TAK-659/CB-659)

Autor: Gordon, Leo I, Karmali, Reem, Kaplan, Jason B, Popat, Rakesh, Burris, Howard A, Ferrari, Silvia, Madan, Sumit, Patel, Manish R, Gritti, Giuseppe, El-Sharkawi, Dima, Chau, F Ian, Radford, John, de Oteyza, Jaime Pérez, Zinzani, Pier Luigi, Iyer, Swaminathan P, Townsend, William, Miao, Harry, Proscurshim, Igor, Wang, Shining, Katyayan, Shilpi, Yuan, Ying, Zhu, Jiaxi, Stumpo, Kate, Shou, Yaping, Carpio, Cecilia, Bosch, Francesc

Publikováno v: Gordon, L I, Karmali, R, Kaplan, J B, Popat, R, Burris, H A, Ferrari, S, Madan, S, Patel, M R, Gritti, G, El-Sharkawi, D, Chau, F I, Radford, J, de Oteyza, J P, Zinzani, P L, Iyer, S P, Townsend, W, Miao, H, Proscurshim, I, Wang, S, Katyayan, S, Yuan, Y, Zhu, J, Stumpo, K, Shou, Y, Carpio, C & Bosch, F 2023, ' Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma : updated data with mivavotinib (TAK-659/CB-659) ', Oncotarget, vol. 14, pp. 57-70 . https://doi.org/10.18632/oncotarget.28352
Scientia

Non-Hodgkin’s lymphoma; SYK inhibitor; Relapsed/refractory Linfoma no Hodgkin; Inhibidor de SYK; Recidivante/refractario Limfoma no Hodgkin; Inhibidor de SYK; Recaiguda/refractària We report an updated analysis from a phase I study of the spleen t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::611458e735d4ba1168636765aa9dcd81
https://ddd.uab.cat/record/271599